Paper41275111
Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.
Takeshima T and 8 others. J Headache Pain, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. Papers, record 41275111. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41275111
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Analgesics | Major topic |
| Migraine Disorders | Major topic |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Chronic Disease | |
| Double-Blind Method | |
| Japan | |
| Treatment Outcome | |
| East Asian People | |
| Antibodies, Monoclonal, Humanized |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05064371 | Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan | Derived from the trial | Yes |
Source ClinicalTrials.gov
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35690723 | European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. | J Headache Pain | 2022 | https://conductscience.org/library/papers/35690723 | PubMed |
| 2 | 39708221 | The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study. | Neurol Ther | 2025 | https://conductscience.org/library/papers/39708221 | PubMed |
| 3 | 22193671 | The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. | Am J Psychiatry | 2011 | https://conductscience.org/library/papers/22193671 | PubMed |
| 4 | 39700106 | Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database. | PLoS One | 2024 | https://conductscience.org/library/papers/39700106 | PubMed |
| 5 | 39661241 | The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region. | Pain Ther | 2025 | https://conductscience.org/library/papers/39661241 | PubMed |
| 6 | 34862581 | Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. | Neurol Ther | 2022 | https://conductscience.org/library/papers/34862581 | PubMed |
| 7 | 35716692 | Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. | Lancet Neurol | 2022 | https://conductscience.org/library/papers/35716692 | PubMed |
| 8 | 21479777 | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). | Qual Life Res | 2011 | https://conductscience.org/library/papers/21479777 | PubMed |
| 9 | 31174464 | Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. | J Headache Pain | 2019 | https://conductscience.org/library/papers/31174464 | PubMed |
| 10 | 35466430 | Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. | Headache | 2022 | https://conductscience.org/library/papers/35466430 | PubMed |
| 11 | 33023473 | Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. | J Headache Pain | 2020 | https://conductscience.org/library/papers/33023473 | PubMed |
| 12 | 32209650 | Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. | Neurology | 2020 | https://conductscience.org/library/papers/32209650 | PubMed |
| 13 | 10146874 | The validity and reproducibility of a work productivity and activity impairment instrument. | Pharmacoeconomics | 1993 | https://conductscience.org/library/papers/10146874 | PubMed |
| 14 | 34013992 | Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. | Headache | 2021 | https://conductscience.org/library/papers/34013992 | PubMed |
| 15 | 29368949 | Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. | Cephalalgia | 2018 | https://conductscience.org/library/papers/29368949 | PubMed |
| 16 | 38523607 | Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. | Front Neurol | 2024 | https://conductscience.org/library/papers/38523607 | PubMed |
| 17 | 39692817 | Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial. | J Patient Rep Outcomes | 2024 | https://conductscience.org/library/papers/39692817 | PubMed |
| 18 | 9595870 | Development and validation of the Migraine-Specific Quality of Life Questionnaire. | Headache | 1998 | https://conductscience.org/library/papers/9595870 | PubMed |
| 19 | 38664605 | Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. | J Headache Pain | 2024 | https://conductscience.org/library/papers/38664605 | PubMed |
| 20 | 28919117 | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | Lancet | 2017 | https://conductscience.org/library/papers/28919117 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| EPTINEZUMAB | CHEMBL3833320 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3833320 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41275111
GET https://conductscience.org/api/papers/v1/41275111/references?page=2